# Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT

> **NCT03861091** · PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 84 (actual)

## Conditions studied

- Lung Neoplasm

## Interventions

- **DRUG:** risedronate
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT03861091
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-12
- **Primary completion:** 2022-03-02
- **Final completion:** 2022-03-02
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2023-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03861091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03861091, "Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03861091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*